Product Name :
D8-MMAF hydrochloride
Description:
D8-MMAF hydrochloride is a deuterated form of MMAF hydrochloride, which is a microtubule disrupting agent.
CAS:
Molecular Weight:
776.47
Formula:
C39H66ClN5O8
Chemical Name:
(2S)-2-[(2R)-2-[(R)-methoxy[(2S)-1-[(3R, 4S, 5S)-3-methoxy-5-methyl-4-[(2S)-3-(H)methyl-N-methyl-2-[(2S)-3-methyl-2-(methylamino)butanamido](2, 3, 4, 4, 4-H)butanamido]heptanoyl]pyrrolidin-2-yl]methyl]propanamido]-3-phenylpropanoic acid hydrochloride
Smiles :
Cl.[2H]C([C@]([2H])(NC(=O)[C@@H](NC)C(C)C)C(=O)N(C)[C@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC1C=CC=CC=1)C(O)=O)OC)[C@@H](C)CC)(C([2H])([2H])[2H])C([2H])([2H])[2H]
InChiKey:
BUPKFQQDMNUXOY-HKTWAXPZSA-N
InChi :
InChI=1S/C39H65N5O8.ClH/c1-12-25(6)34(43(9)38(48)33(24(4)5)42-37(47)32(40-8)23(2)3)30(51-10)22-31(45)44-20-16-19-29(44)35(52-11)26(7)36(46)41-28(39(49)50)21-27-17-14-13-15-18-27;/h13-15,17-18,23-26,28-30,32-35,40H,12,16,19-22H2,1-11H3,(H,41,46)(H,42,47)(H,49,50);1H/t25-,26+,28-,29-,30+,32-,33-,34-,35+;/m0./s1/i4D3,5D3,24D,33D;
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Atomoxetine} medchemexpress|{Atomoxetine} Membrane Transporter/Ion Channel|{Atomoxetine} Purity & Documentation|{Atomoxetine} Formula|{Atomoxetine} manufacturer|{Atomoxetine} Cancer}
Shelf Life:
≥360 days if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
D8-MMAF hydrochloride is a deuterated form of MMAF hydrochloride, which is a microtubule disrupting agent.|Product information|Molecular Weight: 776.47|Formula: C39H66ClN5O8|Chemical Name: (2S)-2-[(2R)-2-[(R)-methoxy[(2S)-1-[(3R, 4S, 5S)-3-methoxy-5-methyl-4-[(2S)-3-(H)methyl-N-methyl-2-[(2S)-3-methyl-2-(methylamino)butanamido](2, 3, 4, 4, 4-H)butanamido]heptanoyl]pyrrolidin-2-yl]methyl]propanamido]-3-phenylpropanoic acid hydrochloride|Smiles: Cl.{{Pembrolizumab} medchemexpress|{Pembrolizumab} Immunology/Inflammation|{Pembrolizumab} Protocol|{Pembrolizumab} Formula|{Pembrolizumab} custom synthesis|{Pembrolizumab} Epigenetics} [2H]C([C@]([2H])(NC(=O)[C@@H](NC)C(C)C)C(=O)N(C)[C@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC1C=CC=CC=1)C(O)=O)OC)[C@@H](C)CC)(C([2H])([2H])[2H])C([2H])([2H])[2H]|InChiKey: BUPKFQQDMNUXOY-HKTWAXPZSA-N|InChi: InChI=1S/C39H65N5O8.PMID:33065702 ClH/c1-12-25(6)34(43(9)38(48)33(24(4)5)42-37(47)32(40-8)23(2)3)30(51-10)22-31(45)44-20-16-19-29(44)35(52-11)26(7)36(46)41-28(39(49)50)21-27-17-14-13-15-18-27;/h13-15,17-18,23-26,28-30,32-35,40H,12,16,19-22H2,1-11H3,(H,41,46)(H,42,47)(H,49,50);1H/t25-,26+,28-,29-,30+,32-,33-,34-,35+;/m0./s1/i4D3,5D3,24D,33D;|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|MMAF shows in vitro cytotoxicity against a panel of cell lines. The IC50 values for Karpas 299, H3396, 786-O and Caki-1 are 119, 105, 257, and 200 nM, respectively. Targeted MMAF is much more potent than the free drug, and that cAC10 conjugates of MMAF display pronounced activities. On a molar basis, the cAC10-L1-MMAF4 is an average of over 2200-fold more potent than free MMAF and is active on all the CD30-positive cell lines tested.|In Vivo:|The maximum tolerated dose in mice of MMAF (>16 mg/kg) is much higher than MMAE (1 mg/kg). cAC10-L1-MMAF4 has an MTD of 50 mg/kg in mice and 15 mg/kg in rats. The corresponding cAC10-L4-MMAF4 ADC was much less toxic, having MTDs in mice and rats of >150 mg/ kg and 90 mg/kg in rats, respectively.|References:|Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.Products are for research use only. Not for human use.|